Rationale for drug development of herbals in oncology: Clinical, industry, and regulatory perspectives

Drug Information Journal

Volumn 33, Issue 4, 1999, Pages 1003-1010

  Richardson, Mary Ann ^a   Tamayo, Carmen ^b   Klein, Agnes ^d   Marcon, Norman ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE

Author keywords

Cancer; Complementary alternative medicine; Herbal products

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER THERAPY; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL TIME; TAXONOMY; TRADITIONAL MEDICINE; VISCUM ALBUM;

EID: 0032738863     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300405     Document Type: Article

References (38)

1. Eisenberg D, Davis R, Ettner S, et al. Trends in alternative medicine use in the United States, 1990-1997 results of a follow-up national survey. JAMA. 1998;280:1569-1575.
2. Fisher P, Ward A. Complementary medicine in Europe. Br Med J. 1994;309:107-111.
3. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet. 1996;347:569-573.
4. Hauser SP. Unproven methods in cancer treatment. Curr Opinion Oncol 1993;5:646-654.
5. Eisenberg D, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: Prevalance, costs, and patterns of use. New Engl J Med. 1993;328:246-252.
6. Cassileth BR, Lusk EF, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Int Med. 1984;101:105-112.
7. American Cancer Society. Unproven methods of cancer management-macrobiotic diets for the treatment of cancer. CA: A Cancer J Clinicians. 1989; 39(4):248-251.
8. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatments in the United States. Cancer. 1992;42:181-191.
9. Richardson MA, Ramirez T, Nanney K, Singletary SE. Alternative/complementary medicine: implications for patient-provider communication. Proceedings of ASCO. 1999;18:590A.
10. Gray RE, Fitch M, Greenberg M, et al. Perspectives of cancer survivors interested in unconventional therapies. J Psychosocial Oncology. 1997;15:149-171.
11. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. The use of complementary health strategies by women with early stage breast cancer. Presented at the American Cancer Society Meeting, 1998.
12. Coppes MJ, Anderson RA, Egeler RM, Wolff JEA. Alternative therapies for the treatment of childhood cancer. New Engl J Med. 1998;339:846-847.
13. Wetzel MS, Eisenberg DM, Kaptchuk TJ. Courses involving complementary and alternative medicine at US medical schools. JAMA. 1998;280:784-787.
14. Astin JA. Why patients use alternative medicine. Results of a national study. JAMA. 1998;279:1548-1553.
15. Hoey J. The arrogance of science and the pitfalls of hope. (Editorial). Canadian Med Assoc J. 1998;159: 803-804.
16. Durant JR. Alternative medicine: an attractive nuisance. (editorial). J Clinical Oncology. 1998;16:1-2.
17. Tannock IF, Warr DG. Unconventional therapies for cancer: a refuge from the rules of evidence? Canadian Med Assoc J. 1998;159:801-802.
18. Office of Alternative Medicine. Washington, DC: First Investigators Meeting; 1994.
19. Cooper RA, Stoflet SJ. Trends in the education and practice of alternative medicine clinicians. Health Aff. (Millwood). 1996;15:226-238.
20. Ernst E, Resch K, White AR. Complementary medicine: what physicians think of it - a meta-analysis. Arch Intern Med. 1995;155:2405-2408.
21. Spiegel D, Stroud P, Fyfe A. Complementary medicines. Wes J Med. 1998;168:241-247.
22. Bourgeault I. Physicians' attitudes toward patients' use of alternative cancer therapies. Can Med Assoc J. 1996;155(12):1679-1685.
23. Angell M, Kassirer P. Alternative medicine - the risks of untested and unregulated remedies. New Engl J Med. 1998;339:839-841.
24. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. New Engl J Med. 1998;339:785-791.
25. Bailar JC, Gornik HL. Cancer undefeated. New Engl J Med. 1997;336(33):1569-1574.
26. Bussing A. Mistletoe therapy and immunological research. Anti-Cancer Drugs (Suppl). 1997;8:S65.
27. Gabius HJ, Andre S, Kaltner J, Siebert HC, von der Lieth CW, Gabius S. The mistletoe myth: claims, reality and provable perspectives. Zeitschrift Fur Arztliche Fortbildung. 1996;90:103-110.
28. Hajto T, Hostanska K, Gabius HJ. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res. 1989;49:4803-4808.
29. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factor alpha, Interleukin 1, and Interleukin 6 by human mononuclear cells exposed to b-Galactoside-specific Lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322-3326.
30. Douwes FR, Wolfrum DI, Migeod F. Results of a prospective randomized study on chemotherapy vs. chemotherapy plus biological response modifier in metastasizing colorectal carcinoma. Krebsgeschehen. 1986;18:155-164.
31. Douwes FR, Kalden M, Frank G, Holzhauer P. Treatment of advanced colorectal carcinoma. Onkologie. 1988.
32. Boie D, Gutsch J. Helixor in cancer of colon and rectum. Schriftenreihe Krebsgeschehen. 1980;23: 65-76.
33. Gutsch J, Berger H, Scholz G, Denck H. Prospective study in radically operated breast cancer with polychemotherapy, Helixor and untreated control. Deutsche Zeitschrift Fur Onkologie. 1988;21:94-101.
34. Warner-Lambert. Warner-Lambert launches quanterra (TM): standardized herbal supplements clinically proven by doctors to be safe and effective -quanterra mental sharpness with ginko biloba and quanterra prostate, with saw palmetto. NewsEdge Corp./Newswire. October 14, 1998.
35. The University of Texas - Houston Center for Alternative Medicine. http://www.sph.tmc.edu/utcam/.
36. Houghton PJ. Establishing identification criteria for botanicals. Drug Inf J. 1998;32:461-469.
37. Lazarowych N, Pekos P. Use of fingerprinting and marker compounds for identification and standardization of botanical drugs: strategies for applying pharmaceutical HPLC analysis to herbal products. Drug Inf J. 1998;32:497-512.
38. Eskinazi DP. Factors that shape alternative medicine. JAMA. 1998;280(18):1621-1623.